Ascentage Pharma Group International (HKG: 6855)

Market Cap	13.17B
Revenue (ttm)	970.30M
Net Income (ttm)	-387.13M
Shares Out	309.89M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,256,800
Open	44.30
Previous Close	44.20
Day's Range	40.60 - 44.30
52-Week Range	15.42 - 48.85
Beta	1.13
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About Ascentage Pharma Group International

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 583
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6855

Financial Performance

In 2023, Ascentage Pharma Group International's revenue was 221.98 million, an increase of 5.85% compared to the previous year's 209.71 million. Losses were -925.64 million, 4.84% more than in 2022.

Financial numbers in CNY